Le Lézard
Classified in: Health
Subjects: PDT, MAT

Pumpkin Spice Fanatics Can Rejoice: LumiZen Pumpkin Spice Full-Spectrum is Here


As Seasonal Flavors Emerge for The Fall, LumiZen Has Announced an All-New Way to Satisfy Pumpkin Spice Cravings

HENDERSON, Nev., Sept. 7, 2022 /PRNewswire/ -- Pumpkin spice flavoring is a mainstay of the fall season, and it has only grown in popularity in recent years. Now, as people seek out their favorite fall flavors, LumiZen Wellness is offering another exciting option.

As the pumpkin spice craze emerged, data was slowly collected about the ongoing popularity of the trend. Now, these statistics show a rapid increase in the market. In 2015, the pumpkin spice market was at $100 million, but three years later, in 2018, the market was at $600 million. Starbucks' Pumpkin Spice Latte is a major source for the craze, but other pumpkin spice products are highly sought after during the fall months, including pumpkin spice lattes, pumpkin spice ice cream, and even pumpkin flavored pet food.

The growing popularity of the CBD market is on a similar track, experiencing flourishing growth in recent years. People seek out CBD products to help alleviate anxiety, depression, chronic pain, and more, and they also seek out CBD's natural healing properties for their pets. The team at LumiZen Wellness is a forward-thinking up and coming CBD company offering a wide range of potent, effective, safe CBD products.

Now, their team says they've intertwined the pumpkin spice craze with CBD in a way that's rarely been seen. LumiZen Wellness is launching a special edition line of Pumpkin Spice 1000mg Full spectrum CBD Tincture exclusively via their website.

Now, carving out its own space in the pumpkin spice industry, LumiZen Wellness is offering a highly sought-after variety of full spectrum CBD. Their all-new Pumpkin Spice 1000mg Full Spectrum CBD Tincture features the allure of pumpkin spice aroma and taste, bringing the CBD experience to a new level. Anyone who is craving pumpkin spice but also looking to relax can enjoy this exciting new blend.

The dedicated staff at LumiZen Wellness work to ensure an unparalleled of transparency and peace of mind, and they do this through the posting of their lab results and certificates of analysis. Anyone interested in CBD but wary of the lab results can visit https://lumizenwellness.com.

"We all see the pumpkin spice craze happen every year, and within the CBD community, there's been a recent demand for pumpkin spice products. So, we took one of our best sellers and did the research and development needed to offer a full spectrum pumpkin spice tincture that can be enjoyed safely," said a spokesperson for LumiZen Wellness.

Learn more about LumiZen Wellness at https://lumizenwellness.com.

Further information about the all-new pumpkin spice CBD tincture from LumiZen Wellness can be found at https://www.pumpkinspicecbd.com/.

CONTACT
Matt Meagher
LumiZen Wellness
Phone: 702-556-6473
Email: [email protected]
Facebook: @lumizenwellness
Instagram: @lumizenwellness
Website: https://lumizenwellness.com 

SOURCE LumiZen Wellness


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: